Genovis AB (publ.) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Genovis AB (publ.) şirketinin toplam hissedar öz sermayesi SEK222.2M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK319.3M ve SEK97.1M dir. Genovis AB (publ.) 'in FAVÖK'ü SEK28.4M faiz karşılama oranı -113.3 dur. Şirketin SEK155.5M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	-113.3x
Nakit	SEK 155.53m
Eşitlik	SEK 222.20m
Toplam yükümlülükler	SEK 97.15m
Toplam varlıklar	SEK 319.35m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5GV 'nin kısa vadeli varlıkları ( SEK199.3M ) kısa vadeli yükümlülüklerini ( SEK22.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5GV şirketinin kısa vadeli varlıkları ( SEK199.3M ) uzun vadeli yükümlülüklerini ( SEK74.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5GV borçsuzdur.

Borcun Azaltılması: 5GV un 5 yıl önce borcu yoktu.

Borç Kapsamı: 5GV un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 5GV şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Genovis AB (publ.) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment improves as stock rises 37%

New major risk - Share price stability

Third quarter 2024 earnings released: EPS: kr0.21 (vs kr0.048 in 3Q 2023)

Genovis AB Launches Fabricator® Xtra

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Second quarter 2024 earnings released: EPS: kr0.027 (vs kr0.23 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022)

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: EPS: kr0.94 (vs kr0.17 in FY 2022)

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: kr0.048 (vs kr0.087 in 3Q 2022)

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Director recently sold €2.2m worth of stock

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021)

Full year 2022 earnings released: EPS: kr0.17 (vs kr0.38 in FY 2021)

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: kr0.01 (vs kr0.016 in 2Q 2021)

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Genovis AB (Publ.) Announces Board Changes

First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021)

Full year 2021 earnings released: EPS: kr0.38 (vs kr0.099 in FY 2020)

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought €5.0k worth of stock

Insider recently bought €5.0k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS kr0.013 (vs kr0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.016 (vs kr0.023 loss in 2Q 2020)

General Counsel recently bought €20k worth of stock

First quarter 2021 earnings released: EPS kr0.011 (vs kr0.031 loss in 1Q 2020)

Full year 2020 earnings released: EPS kr0.099 (vs kr0.15 in FY 2019)

Revenue beats expectations

New 90-day high: €4.62

Genovis AB (publ.) to Report Nine Months, 2021 Results on Nov 11, 2021

New 90-day high: €3.46

Genovis AB and Glykos Finland Oy Partner to Enable New ADC Platform

Revenue misses expectations

Third quarter 2020 earnings released: EPS kr0.02

Genovis AB (publ.), Annual General Meeting, May 20, 2021

New 90-day low: €2.95

Genovis AB (publ.) to Report First Half, 2021 Results on Aug 12, 2021

Earnings released

Genovis AB (publ) (OM:GENO) completed the acquisition of QED Bioscience, Inc.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin